≤240 mg/dL; (2) diabetes, treated with a regimen ofdiet and/or metformin and/or thiazolidinediones (TZDs), which was stable for at least 3 months prior to screening;(3) HbA 1cbetween 6.5 and 11.0%, inclusive; (4) body mass index (BMI) between 27 and 40 kg/m2,i n c l u s i v e ; (5) no history of diabetic ketoacidosis or blood C-peptide ≤1 ng/mL; (6) no clinically signiﬁcant abnormal laboratory test values except for those consistent with type 2 diabetes; and (7) no untreated/unstable cardiovasculardisease. Subjects were excluded (1) if they had clinicallysigniﬁcant comorbid conditions; (2) if they were treatedwith insulin or glyburide/metformin within 3 months ofscreening; (3) if they were treated with miglitol, acarbose,repaglinide, or nateglinid e within 4 weeks of screening; or (4) if they had chronic use of systemic corticosteroids. Study design